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Free radicalsRecently we have shown that hypoxia as well as overexpression of the stable form of hypoxia-inducible fac-
tor-1α (HIF-1α) diminished the expression of interleukin-8 (IL-8) by inhibition of the Nrf2 transcription fac-
tor in HMEC-1 cells. Because HIF isoforms may exert different effects, we aimed to examine the inﬂuence of
HIF-2α on IL-8 expression in endothelial cells. In contrast to HIF-1α, overexpression of HIF-2α obtained by
adenoviral transduction resulted in increased expression of IL-8 in an Nrf2-independent way. Importantly,
HIF-2α augmented the activity of SP-1, a transcription factor involved in IL-8 regulation and known coactiva-
tor of c-Myc. Additionally, HIF-1 decreased, whereas HIF-2 increased, c-Myc expression, and silencing of Mxi-
1, a c-Myc antagonist, restored IL-8 expression downregulated by HIF-1α or hypoxia. Accordingly, binding of
c-Myc to the IL-8 promoter was abolished in hypoxia. Importantly, both severe (0.5% O2) and mild (5% O2)
hypoxia diminished IL-8 expression despite the stabilization of both HIF-1 and HIF-2. This study reveals
the opposite roles of HIF-1α and HIF-2α in the regulation of IL-8 expression in endothelial cells. However,
despite stabilization of both isoforms in hypoxia the effect of HIF-1 is predominant, and downregulation of
IL-8 expression in hypoxia is caused by attenuation of Nrf2 and c-Myc.rs containing HIF-1α or HIF-2α
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license.© 2011 Elsevier Inc.Open access under CC BY license.Hypoxic transcriptional response is primarily mediated by the
hypoxia-inducible factors (HIF-1 and -2), both consisting of α and
β subunits. In contrast to the β subunit, also known as the aryl hydro-
carbon receptor nuclear translocator (ARNT), which is constitutively
expressed, the α subunit is degraded at normal oxygen tension [1].
HIF-1α and HIF-2α are characterized by similar structures. Both are
members of the family of basic helix–loop–helix and PER–ARNT–
SIM domain-containing transcription factors [2,3]. Apart from these
domains, important for DNA binding and dimerization with HIF-1β,
respectively, a central oxygen-dependent degradation domain and
two transactivation domains, the N-terminal activation domain
(NAD) and C-terminal activation domain (CAD), are recognized in
their structures [4]. NAD confers target gene speciﬁcities of HIF-1α
and HIF-2α, whereas the CAD promotes the expression of their com-
mon target genes [5].Under hypoxia, the formation of an active HIF complex fromα and
β subunits occurs in concert with certain factors. The p300/CREB-
binding protein is a central integrating coactivator [6], which, in a
hypoxia-dependent manner, owing to its binding the CAD of HIF-1α
or HIF-2α, enables the recruitment of various accessory cofactors,
such as the steroid receptor coactivator, transcription intermediary
factor-2, or redox factor Ref-1 [4,6]. Interestingly, speciﬁc coactivators
have been found, which take part exclusively in the formation of tran-
scriptional complexes regulating target genes of HIF-2α such as the
NF-κB essential modulator enhancing HIF-2α activity at normoxia
[7], Ets1 regulating the transcription of vascular endothelial growth
factor (VEGF) receptor 2 [8], and Elk-1 regulating erythropoietin
(EPO), CITED-2, and the plasminogen activator inhibitor-1 [9].
Both HIF α subunits recognize the same DNA sequence (5′-(A/G)
CGTG-3′), termed the hypoxia response element (HRE), found within
the promoters or enhancers of target genes. However, differences in
the NAD of the HIF isoforms and the requirement of speciﬁc transcrip-
tional cofactors imply they may regulate the expression of distinct pro-
teins, despite their high structural similarities. Thus, expression
proﬁling and functional studies have revealed that HIF-1α and HIF-
2α regulate both shared and unique target genes. The most common
shared target is VEGF. On the other side, HIF-1α exclusively stimulates
the expression of several glycolytic enzymes, whereas the embryonic
transcription factors Oct-4, cyclin D1, and EPO are upregulated under
hypoxia in a HIF-2α-dependent manner [10–15]. Regulation of gene
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because of the revealed interaction of HIF-1α/HIF-2α and c-Myc/Max
proteins. HIF-2α augments c-Myc activity by stabilizing the c-Myc:
Max complex, which promotes cell cycle progression. In contrast,
HIF-1α inhibits the c-Myc function, resulting in cell cycle arrest at the
G1/S phase [16]. Such action of HIF-1αmay be explained by its binding
to the Max protein and competition with c-Myc, inhibition of c-Myc
protein stability [17], alteration of interaction with the SP-1 transcrip-
tion factor known as the coactivator of c-Myc [16], or induction of the
c-Myc antagonist, Mxi-1 [18]. Importantly, Mxi-1 has been found
to be induced by hypoxia, in a HIF-1α-dependent manner, with con-
comitant downregulation of c-Myc target genes [19,20].
It is well known that hypoxia is a potent inducer of the formation of
new blood vessels by enhancing the expression of VEGF. Interestingly,
we have recently shown that the expression of interleukin-8 (IL-8), an-
other mediator of angiogenesis, tumor growth, and metastasis, is
downregulated by HIF-1α via attenuation of the Nrf2 transcription fac-
tor expression and activity [21]. Moreover, IL-8 has been found to be
signiﬁcantly increased in Mxi-1 knockdown cells [20]. As HIF-1α and
HIF-2α may differ in their functions and as HIF-1α antagonizes the
c-Myc action [18], by enhancing Mxi-1 expression, we hypothesized
that the effects of both subunits on IL-8 expression may be opposite.
In this study we report that in contrast to HIF-1α, overexpression
of HIF-2α resulted in increased expression of IL-8. Accordingly,
HIF-2α enhanced the activity of SP-1, which may regulate IL-8. Fur-
thermore, we revealed that c-Myc is involved in the observed effect
of HIF-2α on IL-8 upregulation, whereas Mxi-1 partially mediated
the opposite effect of HIF-1α. The different functions of the HIF α iso-
forms in the regulation of IL-8 may add to our understanding of in-
ﬂammatory processes, hypoxic response, and further blood vessel
formation.
Materials and methods
Cell culture and incubation experiments
Human microvascular endothelial cells (HMEC-1) were cultured
under standard conditions (5% CO2, 37 °C, 95% humidity) as described
previously [21]. Brieﬂy, they were incubated in MCDB 131 medium
(Gibco) containing 10% fetal bovine serum, L-glutamine (2 mM), epi-
dermal growth factor (10 ng/ml), hydrocortisone (1 μg/ml), and anti-
biotics, 50 U/ml penicillin and 50 μg/ml streptomycin.
Hypoxia chambers were used as previously described [21]. In
brief, after a change for fresh medium, culture dishes were placed in
a humidiﬁed airtight incubator with inﬂow and outﬂow valves and
a hypoxic gas mixture (0.5% O2, 5% CO2, and balance N2). Where indi-
cated, 5% O2 was used in the hypoxic gas mixture. Then the chamber
was kept at 37 °C for 6 or 24 h. At the same time, control normoxic
cells were placed in an incubator containing 21% O2, 5% CO2, 74% N2,
at 37 °C.
Plasmid transfection
Plasmid transfections were performed in cells growing to 60–80%
conﬂuence in 24-well plates, using 0.5 μg of DNA mixed with 2.5 μl of
SuperFect (Qiagen) per well, according to the vendor's protocol. After
2.5 h the cells were washed and overlaid with a regular culture medi-
um for 24 h and, where indicated, were transduced with adenoviral
vectors for the next 48 h or incubated under hypoxia for the next 24 h.
The plasmid containing the full-length promoter of the IL-8 gene
driving luciferase expression was a kind gift from Dr. Rainer de Martin
(Vienna, Austria). The construct containing the full-length promoter
of the VEGF gene driving luciferase expression was kindly provided by
Dr. Hideo Kimura (Chiba, Japan) [22]. The pNFκB-SEAP and pAP-1-
SEAP vectors, containing the NF-κB and AP-1 binding regions connected
to the secreted alkaline phosphatase (SEAP) reporter gene, werepurchased from Clontech. The construct containing the antioxidant re-
sponse element (ARE) sequences driving the expression of luciferase
was kindly supplied by Dr. J.A. Johnson (University of Wisconsin,
Madison,WI, USA) [23]. The SP-1-luc plasmid, containing the upstream
region of the VEGF promoter from −133 to +3 bp cloned into a
pAH1409 vector, was kindly supplied by Dr. Ulrike Fiedler (Tumor Cell
Biology, Freiburg, Germany). The pCMV-lacZ vector containing the
β-galactosidase gene driven by the CMV promoter was purchased
from Promega and was cotransfected into cells together with one of
the above-described reporter plasmids as an internal control. The en-
zyme activity of luciferase was determined in cell lysates according to
the manufacturer's instructions (Promega). The enzyme activity of
SEAP was assessed in culture medium using a chemiluminescence
assay according to the vendor's protocol (Clontech). The activity of
SEAP or luciferasewas normalized to β-galactosidase activity. Addition-
ally, a pBluescript vector encoding SP-1 transcription factor cDNA under
the CMV promoter (Addgene) was used to obtain SP-1 overexpression.
Transfection with small interfering RNA
Cells were transfected with 50 nM chemically synthesized siRNA
targeted against human Nrf2 mRNA (sense, 5′-UGACAGAAGUUGA-
CAAUUATT-3′; antisense, 5′-UAAUUGUCAACUUCUGUCATT-3′) or
human Mxi-1 mRNA (Santa Cruz Biotechnology, Cat. No. sc-35835)
or human c-Myc mRNA (Ambion, Cat. No. AM4250). As a control a
scrambled siRNA (Santa Cruz Biotechnology, Cat. No. sc-37007) was
used. Brieﬂy, cells were seeded into 24-well plates one day before
transfection to obtain conﬂuence of about 50–70%. siRNA and Lipofec-
tamine 2000 (Invitrogen) were separately diluted in Opti-MEM with-
out serum, incubated for 5 min at room temperature, combined, and
incubated for the next 20 min at room temperature. In some experi-
ments JetPrime (Polyplus Transfection) was used instead of Lipofec-
tamine 2000 according to the vendor's protocol. Twenty-four hours
after transfection the cells were placed in a normoxic or hypoxic at-
mosphere for the next 24 h. For the other experiments, 24 h after
transfection cells were transduced with adenoviral vectors (see
below) for the next 48 h. Every 24 h the medium was replaced with
fresh medium.
Transduction with adenoviral vectors
Adenoviral vectors containing HIF-1α or HIF-2α cDNA (AdHIF-1α,
AdHIF-2α) were a kind gift from Professor Seppo Yla-Herttuala and
Dr. Anna Liisa-Levonen (Kuopio, Finland). The AdHIF-1α vector was
generated as described previously [24]. Brieﬂy, a construct was stabi-
lized against prolyl hydroxylation and subsequent ubiquitin-mediated
proteolytic degradation under normoxic conditions by point mutations
(P402A/P563A). A control vector harboring green ﬂuorescent protein
(GFP) cDNA (AdGFP) was produced using the AdenoX system as de-
scribed previously [21]. Transduction with adenoviral vectors contain-
ing cDNA for HIF-1α, HIF-2α, or GFP, as a control, was performed, and
after 48 h the appropriate tests were conducted.
Site-directed mutagenesis
Point mutations were introduced into the IL-8 promoter using the
QuickChange II-E site-directed mutagenesis kit (Stratagene) accord-
ing to the manufacturer's instructions. Two guanines at positions
1376 and 1377 (Homo sapiens IL-8 GenBank ID M28130.1), predicted
as a part of the SP-1 binding site using Alibaba 2.1 computational
analysis, were changed to adenine and thymine, respectively. The se-
quences of the sense and antisense oligonucleotides were as follow:
5′-CTCAGGTTTGCCCTGAGATGATGGGCCATCAGTTGC-3′ and 5′-GCAA
CTGATGGCCCATCATCTCAGGGCAAACCTGAG-3′. Introduction of mu-
tations was veriﬁed by DNA sequencing.
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Total RNA was isolated by a phenol–chloroform extraction. In
brief, cells cultured in a 24-well plate were washed with phosphate-
buffered saline (PBS), overlaid with 400 μl of fenozol (A&A Biotech-
nology), and mixed with 100 μl of chloroform. After centrifugation
(30 min, 10,000 g, 4 °C), an upper aqueous phase was collected and
subjected to ethanol precipitation. The RNA pellet was dissolved in
nuclease-free water. Reverse transcription reaction was carried out
on 1 μg of total RNA for 1 h at 42 °C using oligo(dT) primers and
RevertAid reverse transcriptase (Fermentas), according to the ven-
dor's instructions. Quantitative RT-PCR was performed in a StepOne-
Plus real-time PCR system (Applied Biosystems) in a mixture
containing SYBR Green PCR Master Mix (Sigma), speciﬁc primers,Fig. 1. Opposite effects of HIF-1α and HIF-2α on IL-8 expression. (A) Cells were transduce
AdGFP as a control. Nontransduced cells were used as an additional control. Overexpression
are shown. (B) Cells were cotransfected with plasmid containing the full-length promoter o
gene (100 ng) as an internal control and after 24 h were transduced with AdHIF-1α, AdHIF-2
moter activity was potently induced in response to HIF-2α overexpression. (C, E) Real-time
HIF-2α adenoviral vectors. (D, F) ELISA was performed to assess the IL-8 protein level after
AdHIF-2α increased IL-8 expression at the level of both mRNA and protein. Each bar repr
*pb0.05, comparing AdGFP vs AdHIF-1α or AdHIF-2α.and 50 ng of cDNA in a total volume of 15 μl. The EF2 housekeeping
gene was used as a reference.
Chromatin immunoprecipitation (ChIP)
Cells were cultured under standard or hypoxic conditions, and
ChIP analyses were performed as previously described [25], with
minor changes. Brieﬂy, cells were cultured at 21, 5, or 0.5% O2 for
6 h, before they were ﬁxed with 1% formaldehyde for 20 min. The im-
munoprecipitation was performed with antibodies against c-Myc
(Cat. No. sc-788, Santa Cruz Biotechnology), SP-1 (Cat. No. 07–645,
Millipore), or IgG (Cat. No. 309-005-003, Jackson ImmunoResearch)
as a negative control. DNA was ampliﬁed by real-time PCR using the
Power SYBR Green PCR Master Mix (Applied Biosystems). Primersd for 48 h with 10, 50, and 100 MOI of AdHIF-1α and AdHIF-2α as well as 100 MOI of
of HIF-1α and HIF-2αwas conﬁrmed byWestern blotting; representative immunoblots
f the IL-8 gene driving luciferase expression (500 ng) and plasmid containing the LacZ
α, and AdGFP for the next 48 h. Next, the activity of luciferase was measured. IL-8 pro-
PCR was performed to examine the IL-8 mRNA level after transduction with HIF-1α or
48 h transduction with adenoviral vectors. In contrast to AdHIF-1α, transduction with
esents the mean±SD of two to six independent experiments performed in duplicate.
Fig. 2. Increased expression of VEGF after HIF-1α and HIF-2α. (A) Cells were cotrans-
fected with plasmid containing the full-length promoter of the VEGF gene driving lucifer-
ase expression (500 ng) and plasmid containing the LacZ gene (100 ng) as an internal
control and after 24 h transduced with AdHIF-1α, AdHIF-2α, or AdGFP for the next
48 h. As shown by measurement of luciferase activity, both HIF-1α and HIF-2α activated
VEGF transcription. (B) Real-time PCR and (C) ELISA were performed to examine the
mRNA and protein level of VEGF, respectively, after 48 h of transduction with adenoviral
vectors. Both HIF isoforms enhanced VEGF production, but the effect of HIF-2αwas more
potent. Each bar represents the mean±SD of three to six independent experiments per-
formed in duplicate. *pb0.05, comparing AdGFP vs AdHIF-1α or AdHIF-2α, #pb0.05,
comparing AdHIF-1α vs AdHIF-2α.
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IL-8 promoter (region −121 to +5), 5′-AGGTTTGCCCTGAGGGGA
TGGG-3′ and 5′-ATGGAGTGCTCCGGTGGCTTT-3′, or one of the two
c-Myc binding sites within the IL-8 promoter: ﬁrst (region −802 to
−611) 5′-CTCAATGCTTGCTCCAACT-3′ and 5′-TTCTGAGTAATGTGGG
GGATCT-3′, second (region−417 to−226) 5′-GCTGGCTTATCTTCAC-
CATCA-3′ and 5′-GCTCCACAATTTGGTGAATTAT-3′. The mean of two
experiments is shown.
Western blotting
Cells were lysed in ice-cold PBS containing 1% Triton X-100
(Fluka) and 10 μg/ml of each of the following protease inhibitors:
phenylmethylsulfonyl ﬂuoride, leupeptin, and aprotinin (Sigma).
Samples were centrifuged for 10 min, 8000 g at 4 °C, and clear super-
natants were collected. 30–50 μg of protein was loaded onto a 10%
SDS–PAGE gel followed by 2.5 h electrotransfer to nitrocellulose
membrane Protran (PerkinElmer Life Sciences). After blocking in 5%
nonfat milk for 1 h at room temperature, membranes were probed
with polyclonal antibodies against HIF-1α (Cat. No. sc-10790),
HIF-2α (Cat. No. sc-28706), Nrf2 (Cat. No. sc-13032), Bach1 (Cat.
No. sc-14699), c-Myc (Cat. No. sc-788) (Santa Cruz Biotechnology);
HO-1 (Stressgen, Cat. No. SPA-894); or α-tubulin (Calbiochem, Cat.
No. CP06), as a loading control, overnight at 4 °C, followed by HRP-
linked secondary antibodies (Cell Signaling Technology) for 45 min
at room temperature. All antibodies were diluted in 0.05% Tween con-
taining PBS with 5% nonfat dry milk. Visualization was performed
using SuperSignal West Pico chemiluminescence substrate (Pierce
Biotechnology) according to the manufacturer's instructions.
Measurement of protein synthesis by ELISA
IL-8 and VEGF concentrations in the cell culture medium were de-
termined using ELISA according to the vendor's protocols (R&D
Systems).
Immunoﬂuorescence for detection of HIF α isoforms
Cells were grown on chamber slides under standard or hypoxic con-
ditions for 24 h and then theywere ﬁxed in 4% formaldehyde for 30 min
at room temperature. After being washed with PBS containing ions, the
cells were permeabilized using 0.2% Triton X-100 for 20 min at room
temperature and then blocked with 10% goat serum for 1 h. Slides
were probed with polyclonal antibodies against HIF-1α or HIF-2α
(Santa Cruz Biotechnology) overnight at 4 °C. After awashwith PBS, sec-
ondary polyclonal FITC (green) antibody (Cappel) or Alexa Fluor 546
(red) antibody (Invitrogen) was added together with 1 μg/ml Hoechst
dye (for nuclear staining-blue; Sigma) for 1 h at room temperature. All
antibodies were diluted in 5% goat serum in PBS. Cells were washed
with PBS and observed under ﬂuorescence microscope (Nikon).
Statistical analysis
All experiments were performed in duplicate and most were repeat-
ed three times. All data are presented as means±standard deviation
(SD) andwere analyzed by analysis of variance followed by a Bonferroni
post hoc test for multiple comparisons or by a Student t test for two-
group comparisons. Differences were accepted as statistically signiﬁcant
at pb0.05.
Results
Opposite effects of HIF-1α and HIF-2α on IL-8 expression
To obtain HIF-α isoform overexpression, HMEC-1 cells were trans-
duced with adenoviral vectors carrying HIF-1α or HIF-2α cDNA.Increased levels of HIF proteins at various multiplicities of infection
(MOI) of the adenoviral vectors (10, 50, 100) were conﬁrmed byWest-
ern blotting (Fig. 1A). As controls, AdGFP-treated and nontransduced
cells were used. As expected, AdHIF-1α and AdHIF-2α signiﬁcantly in-
creased in a concentration-dependent manner the protein levels of
HIF-1α and HIF-2α, respectively, compared to AdGFP-transduced and
nontransduced cells (Fig. 1A). The high efﬁciency of transduction was
conﬁrmed by detection of GFP expression (not shown).
We have recently shown that expression of IL-8 is downregulated
by hypoxia or HIF-1α in an Nrf2-dependent manner [21]. Because HIF
isoforms may exert different effects, we aimed to examine the inﬂu-
ence of HIF-2α on IL-8 expression. HMEC-1 cells were transiently
transfected with plasmid containing the full-length promoter of the
IL-8 gene driving luciferase expression and subsequently transduced
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activity of luciferase was strongly enhanced after HIF-2α, but just
slightly and insigniﬁcantly after HIF-1α (Fig. 1B). Accordingly,
HIF-2α increased IL-8 expression at the level of mRNA and protein,
as shown by real-time PCR and ELISA, respectively (Figs. 1C and D).
In contrast, AdHIF-1α diminished IL-8 mRNA and protein (Figs. 1E
and F). Of note, neither HIF-1α nor HIF-2α overexpression caused
changes in the expression of other proinﬂammatory cytokines, IL-6
and IL-1β, as tested by ELISA (not shown).
To conﬁrm the efﬁciency of adenoviral vector transduction we
checked the expression of VEGF, a known common target gene ofFig. 3. HIF-2α increases IL-8 expression independent of Nrf2. (A–D) Cells were transduced f
to examine the mRNA levels of Nrf2, HO-1, NQO1, and Bach1. Western blotting was done us
Note a decrease in Nrf2 and its target genes’ expression and a concomitant increase in the
siRNA targeted against Nrf2 mRNA or scrambled siRNA. Nrf2 siRNA abolished the Nrf2 mRNA
fection with siRNA against Nrf2 mRNA or scrambled siRNA followed by 48 h transduction wi
tion compared to cells transduced with the AdGFP vector, in which Nrf2 was also silenced. E
duplicate. *pb0.05, comparing AdGFP vs AdHIF-1α or AdHIF-2α.HIF isoforms. Studies using the construct containing the full-length
promoter of the VEGF gene driving luciferase expression showed
that both HIF-1α and HIF-2α activate VEGF transcription (Fig. 2A).
The levels of mRNA (Fig. 2B) and protein (Fig. 2C) were also in-
creased. Notably, HIF-2α induced VEGF expression more potently
than HIF-1α at both mRNA and protein levels (Figs. 2B and C).
HIF-2α increases IL-8 expression independent of Nrf2
HIF-1α decreases the IL-8 level by inhibiting the Nrf2 transcrip-
tion factor [21], a known regulator of antioxidant genes includingor 48 h with AdHIF-1α, AdHIF-2α, or AdGFP as a control. Real-time PCR was performed
ing antibodies against Nrf2, HO-1, and Bach1; representative immunoblots are shown.
expression of Bach1, the Nrf2 repressor. (E) Real-time PCR after 48 h transfection with
expression. (F) ELISA was performed to assess the protein level of IL-8 after 24 h trans-
th AdHIF-2α or AdGFP. Silencing of Nrf2 did not inﬂuence HIF-2α-induced IL-8 produc-
ach bar represents the mean±SD of two to six independent experiments performed in
1887U. Florczyk et al. / Free Radical Biology & Medicine 51 (2011) 1882–1892heme oxygenase-1 (HO-1) (for review see [26]). Therefore, we exam-
ined if the upregulation of IL-8 by HIF-2α can be mediated by an in-
crease in Nrf2. The obtained results showed that, at both the mRNA
and the protein level, Nrf2 is downregulated by HIF-1α and HIF-2α
(Fig. 3A). In accordance, the expression of HO-1 and NAD(P)H:qui-
none oxidoreductase (NQO1), the other known target gene of Nrf2,
was also reduced (Figs. 3B and C, respectively). Furthermore, afterFig. 4. HIF-2α overexpression increases SP-1 activity. (A) SP-1 transcription factor binding s
fected with the pSP-1-luc vector containing the SP-1 binding site driving luciferase expressi
after 24 h transduced with AdHIF-1α, AdHIF-2α, or AdGFP for the next 48 h. As shown by m
was performed to examine the mRNA level of a TP gene containing binding sites for SP-1 af
only by HIF-2α (a similar tendency of increase in TP was noted in three independent expe
protein level of IL-8, respectively, after 48 h transduction with AdHIF-2α or AdGFP togeth
HIF-2α on IL-8 was partially reversed by mithramycin A, particularly at the mRNA level. (F) C
plasmid (100 ng). As shown by ELISA, SP-1 overexpression tended to increase IL-8 productio
at guanine residues (in red in (A)). Such mutation did not change HIF-2α-induced IL-8 pro
ments performed in duplicate. *pb0.05, comparing AdGFP vs AdHIF-1α or AdHIF-2α; #pb0
stimulated.transduction with either of the HIF α subunits we observed a con-
comitant increase in the expression of Bach1, the Nrf2 repressor
(Fig. 3D). Therefore, similar inhibitory effects of HIF-1α and HIF-2α
on Nrf2 suggest that the HIF-2α-induced enhancement of IL-8 level
is not dependent on Nrf2.
To further conﬁrm this supposition, cells were transfected with 50
nM chemically synthesized siRNA targeted against human Nrf2ite found in the promoter of IL-8 using the Alibaba 2.1 program. (B) Cells were cotrans-
on (500 ng) and a plasmid containing the LacZ gene (100 ng) as an internal control and
easurement of luciferase activity, HIF-2α augmented SP-1 activity. (C) Real-time PCR
ter 48 h transduction with AdHIF-1α, AdHIF-2α, or AdGFP. TP mRNA was upregulated
riments). (D) Real-time PCR and (E) ELISA were performed to examine the mRNA and
er with stimulation with 10 μM SP-1 inhibitor, mithramycin A. Note that the effect of
ells were transfected for 48 h with the pCMV-SP-1 vector (500 ng) or control Bluescript
n. (G) SP-1 transcription factor binding site found in the promoter of IL-8 was mutated
moter activity. Each bar represents the mean±SD of three to six independent experi-
.05, comparing AdGFP control vs AdGFP stimulated or AdHIF-2α control vs AdHIF-2α
Fig. 5. Effect of severe (0.5% O2) and mild (5% O2) hypoxia on IL-8 expression and SP-1 activity. (A) ELISA was done to assess the IL-8 protein level after 24 h of normoxia (21% O2)
and mild (5% O2) and severe (0.5% O2) hypoxia. Note the decrease in IL-8 production under both conditions. (B) As shown by immunocytochemistry, both HIF subunits were ac-
tivated in HMEC-1 cells under 0.5 and 5% O2; representative staining is shown (original magniﬁcation 100×). (C) Cells were cotransfected with pSP-1-luc vector containing the SP-1
binding site driving luciferase expression (500 ng) and a plasmid containing the LacZ gene (100 ng) as an internal control and after 24 h incubated under 21, 5, or 0.5% O2 for the
next 24 h. Then the luciferase activity was measured. (D) ChIP assay was done to check the SP-1 binding to the IL-8 promoter under severe and mild hypoxia (6 h). Antibodies
against IgG and SP-1 (anti-SP-1) were used. The SP-1 binding site within the IL-8 promoter was ampliﬁed using real-time reverse transcription–PCR as described under Materials
and methods. Both SP-1 activity (C) and SP-1 binding to the IL-8 promoter (D) were slightly affected under both hypoxic conditions, but particularly under 5% O2. Each bar repre-
sents the mean±SD of two to ﬁve independent experiments. *pb0.05, comparing 21% vs 0.5 or 5% O2.
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AdGFP as a control. Inhibition of Nrf2 signiﬁcantly diminished the ex-
pression of IL-8, in both cells transduced with either AdGFP or AdHIF-
2α (Fig. 3F). However, it did not attenuate the upregulation rate of IL-
8 in response to HIF-2α (2.07- and 5.21-fold increase in scrambled
siRNA and siRNA against Nrf2-treated cells, respectively). This con-
ﬁrms the important role of Nrf2 in regulation of IL-8 expression but
not as an effector in the HIF-2-dependent pathway.HIF-2α overexpression increases SP-1 activity
An analysis of the IL-8 promoter revealed the presence of consen-
sus sequences of the Nrf2, NF-κB, AP-1, and SP-1 transcription factorsFig. 6. c-Myc and Mxi-1 are involved in different regulation of IL-8 expression by HIF isoform
incubation of cells under severe (0.5% O2) hypoxia. Note the tendency toward increase in M
to check c-Myc binding to the IL-8 promoter ((C) region−802 to−611 and (D) region−4
Myc) were used. Binding sites of c-Myc within the IL-8 promoter were ampliﬁed using real
binding under hypoxic conditions. (E) Real-time PCR was performed to examine c-Myc mRN
were transduced for 48 h with AdHIF-1α, AdHIF-2α, or AdGFP as a control. As shown by W
expression of c-Myc protein; the representative immunoblot is shown. (G) ELISA was perfo
mRNA or scrambled siRNA as a control and incubation under normoxic or hypoxic condition
fection with siRNA against Mxi-1 mRNA or scrambled siRNA as a control and 48 h transduct
and the hypoxia-dependent diminishment of IL-8. (I) ELISA was done to assess IL-8 protein
control and 48 h transduction with AdHIF-2α or AdGFP. c-Myc siRNA partially reversed HIF-
dent experiments performed in duplicate or (I) a representative experiment is shown. *pb
comparing scrambled siRNA vs siRNA against Mxi-1.(Fig. 4A). To investigate their involvement in regulation of IL-8 ex-
pression we used the pNFκB-SEAP and pAP-1-SEAP vectors, contain-
ing the NF-κB and AP-1 binding regions connected to the secreted
alkaline phosphatase reporter gene, as well as the pSP-1-luc and
pARE-luc vectors containing the SP-1 binding site or ARE (Nrf2 bind-
ing site), respectively, driving luciferase expression. After transfec-
tion, the cells were transduced with adenoviral vectors for 48 h and
subsequently reporter gene expression was examined. In case of
pNFκB-SEAP and pAP-1-SEAP we did not observe any signiﬁcant dif-
ferences in SEAP activity between cells transduced with AdGFP or
AdHIF-1α or AdHIF-2α (not shown). Importantly, luciferase activity
after transfection with the pSP-1-luc vector was signiﬁcantly in-
creased in response to HIF-2α overexpression in comparison to GFP
or HIF-1α (Fig. 4B). Furthermore, thymidine phosphorylase (TP), ans. Real-time PCR was performed to examine (A) Mxi-1 and (B) c-Myc mRNA after 24 h
xi-1 and decrease in c-Myc expression under hypoxia. (C, D) ChIP assay was performed
17 to−226) under hypoxic conditions (6 h). Antibodies against IgG and c-Myc (anti-c-
-time PCR as described under Materials and methods. Note a strong decrease in c-Myc
A after 48 h transduction with AdHIF-1α. AdHIF-1α diminished c-Myc mRNA. (F) Cells
estern blotting, in contrast to HIF-1α, overexpression of HIF-2α resulted in increased
rmed to assess the IL-8 protein level after 24 h transfection with siRNA against Mxi-1
s for the next 24 h. (H) ELISA was done to assess the IL-8 protein level after 24 h trans-
ion with AdHIF-1α or AdGFP. Silencing of Mxi-1 by siRNA reversed both the AdHIF-1α-
level after 24 h transfection with siRNA against c-Myc mRNA or scrambled siRNA as a
2α-induced IL-8 expression. Each bar represents the mean±SD of two to four indepen-
0.05, comparing normoxia vs hypoxia or AdGFP vs AdHIF-1α or AdHIF-2α; #pb0.05,
1889U. Florczyk et al. / Free Radical Biology & Medicine 51 (2011) 1882–1892example of an SP-1 target gene, containing binding sites for SP-1 in its
promoter region, tended to be upregulated only by HIF-2α, as shown
by real-time PCR (Fig. 4C). For inhibition of SP-1 activity 10 μM
mithramycin A was applied 24 h before the end of the experiment.Dimethyl sulfoxide at an appropriate concentration was included in
the control. Importantly, the effect of HIF-2α on IL-8, as well as TP ex-
pression, was reversed by mithramycin A (Figs. 4D and 3E; not shown
for TP).
Fig. 7. Proposed mechanism of regulation of IL-8 expression by interaction of c-Myc/Max, SP-1, and HIF-1α/HIF-2α.
1890 U. Florczyk et al. / Free Radical Biology & Medicine 51 (2011) 1882–1892To further examine the role of SP-1 in HIF-2α-mediated upregula-
tion of IL-8 we overexpressed SP-1 using the pCMV-SP-1 plasmid. As
expected, SP-1 overexpression tended to increase IL-8 production
(Fig. 4F). Then we performed site-directed mutagenesis and mutated
two guanine residues in the predicted SP-1 binding site in the pro-
moter region of IL-8. However, after transfection of HMEC-1 cells
with the mutated form of the pIL-8-luc vector, we did not observe a
decrease in the level of IL-8 promoter activity after subsequent trans-
duction with AdHIF-2α in comparison to the wild-type vector
(Fig. 4G). This suggests that the effect of SP-1 on IL-8 expression
may be rather indirect.
Severe and mild hypoxia evoke similar effects on IL-8 expression
The level of oxygen in different tissues can vary and the inﬂuence
of moderate and strong hypoxia on gene expression can be different.
Indeed, HIF-2 was suggested to mediate hypoxic responses under
moderate hypoxia (5% O2), and HIF-1 may be stabilized at lower oxy-
gen tension (reviewed in [27]). Hence, one may expect that the oppo-
site effects of two HIF isoforms may be detected under different
hypoxia levels.
In our hands, however, the production of IL-8 was decreased to
similar extents by both 0.5 and 5% oxygen (Fig. 5A). Furthermore
both, HIF-1α and HIF-2α were activated in HMEC-1 cells under
both severe (0.5% O2) and mild (5% O2) hypoxia (Fig. 5B). According-
ly, we showed that SP-1 activity detected in the reporter gene assay
(Fig. 5C), as well as SP-1 binding to the IL-8 promoter, revealed by
ChIP analysis (Fig. 5D), was slightly altered under both hypoxic con-
ditions, but particularly under 5% O2.
c-Myc and Mxi-1 are involved in different regulation of IL-8 expression
by HIF isoforms
Recent studies by Yoo and coworkers revealed that IL-8 is upregu-
lated by the silencing of Mxi-1, a c-Myc antagonist [20]. Moreover,
HIF-2αwas shown to increase, whereas HIF-1α decreased, c-Myc activ-
ity by inducingMxi-1 [18] or by alteration of the interaction with SP-1, a
coactivator of c-Myc [16]. Finally, Mxi-1 is induced by hypoxia, in a HIF-
1α-dependentmanner, with concomitant downregulation of c-Myc tar-
get genes [19,20]. Thus, we hypothesized that the observed effects of HIF
isoforms on IL-8 expression may be related to Mxi-1/c-Myc proteins.
We observed a tendency of augmentation of Mxi-1 in severe hypox-
ia (0.5% O2) and a signiﬁcant decrease in c-Myc expression (Figs. 6A
and B, respectively). In accordance with the latter, using a ChIP assay,
we demonstrated that c-Myc binding to both binding sites within the
IL-8 promoter (region−802 to−611 and−417 to−226) is markedly
decreased under hypoxic conditions (Figs. 6C and D).
Moreover, transduction of cells with AdHIF-1α diminished c-Myc
(Fig. 6E). Transduction of cells with AdHIF-2α did not inﬂuence the
level of c-Myc mRNA (not shown), but, in contrast to HIF-1α, overex-
pression of the HIF-2α isoform resulted in increased expression of the
c-Myc protein (Fig. 6F). To further conﬁrm the involvement of Mxi-1
in the effect of HIF-1α on the decrease of IL-8 expression we used
siRNA against Mxi-1 and incubated cells under severe hypoxia (0.5%O2) or transduced themwith AdHIF-1α. In both cases, siRNA transfec-
tion reversed the downregulation of IL-8 (Figs. 6G and H). On the
other hand, treatment of cells with siRNA against c-Myc partially re-
versed the induction of IL-8 expression after AdHIF-2α (Fig. 6I).
Discussion
The salient ﬁnding of this study is the demonstration of the differ-
ent roles of HIF isoforms in regulation of IL-8 expression in endothe-
lial cells. In contrast to HIF-1α, overexpression of HIF-2α results in a
signiﬁcantly increased level of IL-8. We suggest the involvement of
SP-1 and c-Myc in the HIF-2α-dependent IL-8 upregulation, whereas
inhibition of both SP-1 and c-Myc, as well as upregulation of Mxi-1, a
c-Myc antagonist, mediates the action of hypoxia/HIF-1α. Moreover,
despite stabilization of both isoforms in hypoxia the effect of HIF-1α
is predominant and downregulation of IL-8 expression in hypoxia is
caused by attenuation of Nrf2 [21] and c-Myc.
HIF-1α and HIF-2α are the most extensively studied and under-
stood of the three HIF α isoforms. HIF-1α has been recognized to con-
trol more than 100 target genes, and more than 2% of all human genes
are suggested to be either directly or indirectly regulated by this fac-
tor in endothelial cells [28]. Recent reports have also revealed a num-
ber of selective HIF-2α-responsive genes [13,29]. Although HIF-1α
and HIF-2α share signiﬁcant sequence homology, they have unique
tissue distributions, embryonic deletion phenotypes, and effects on
blood vessel formation during tumorigenesis [10–15,30]. Accordingly,
differences exist between the transactivation domains of HIF isoforms
[5], implying HIF-1α and HIF-2αmay require different transcriptional
cofactors to regulate distinct target genes. Interestingly, in addition to
coactivators shared by both HIF isoforms, speciﬁc ones have been
found, which take part exclusively in the formation of a transcription-
al complex regulating target genes of HIF-2α.
We revealed IL-8 as a new candidate for differential regulation by
HIF-1α and HIF-2α. Recently we have shown that expression of IL-8
is reduced after overexpression of the stable form of HIF-1α or
under hypoxic conditions [21]. In this study we report the opposite
action of HIF-2α, which strongly upregulated the expression of IL-8
at the levels of promoter activity, mRNA, and protein. HIF-1α de-
creased the IL-8 level by inhibiting Nrf2 expression and activity,
with the concomitant induction of Bach1, a repressor of Nrf2 tran-
scriptional activity. Similarly, the expression of HO-1 was affected
by HIF-1α via Nrf2 inhibition [21]. However, the effect of HIF-1 on
IL-8 expression is not mediated by HO-1. Our data indicate that an in-
crease in IL-8 after AdHIF-2α was not associated with Nrf2, because
we observed a similar downregulation of Nrf2 and upregulation of
Bach1 after overexpression of both HIF-1α [21] and HIF-2α (this
study). Moreover, searching for other mediators of HIF-2α, we ex-
cluded AP-1 and NF-κB, transcription factors known to regulate IL-8
expression. Instead, the activity of SP-1, whose binding site is present
in the promoter of IL-8, was augmented after AdHIF-2α transduction.
Furthermore, the effect of AdHIF-2α on IL-8 upregulation was re-
versed by the SP-1 inhibitor mithramycin A, thereby suggesting the
SP-1-dependent induction of IL-8 by HIF-2α. Interestingly, SP-1 direct
binding to the IL-8 promoter was not fundamental for HIF-2α action,
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tated SP-1 binding site. Thus, in addition to binding of SP-1 to the IL-8
promoter under basal conditions other factors are probably involved
in the upregulation of IL-8 in response to HIF-2α overexpression. In-
deed, our data suggest that diminishment of IL-8 by hypoxia or HIF-1
and acceleration of IL-8 expression by HIF-2 might be dependent on
the opposite effects on c-Myc activity.
The c-Myc transcription factor regulates the expression of genes
involved in cell proliferation, apoptosis, glucose, and energy metabo-
lism and is overexpressed in many tumors [31]. It heterodimerizes
with the Max protein and binds to consensus E-box elements in the
target genes [32]. Transcriptional repressors belonging to the Mad
family (Mad1, Mad2/Mxi1, Mad3, Mad4) are known to be regulated
inversely compared to c-Myc protein [4,33].
It has been shown that HIF-2α promotes cell-cycle progression in
hypoxic renal cell carcinoma (RCC) and multiple other cell lines. Im-
portantly, this correlated with enhanced c-Myc promoter binding,
transcriptional effects on both activated and repressed target genes,
and interactions with SP-1, Miz1, and Max [16]. Thus, HIF-2α has
been shown to enhance c-Myc activity. HIF-1α, on the other hand,
acted in the opposite way and inhibited c-Myc function, causing cell
cycle arrest at the G1/S phase. In their study on RCC, Gordan and co-
workers [16] proposed that HIF-1α speciﬁcally disrupts c-Myc:Max
and c-Myc:SP-1 complexes, allowing more Mad:Max interaction and
DNA binding. On the other hand, they hypothesized that HIF-2α sta-
bilizes c-Myc:Max complexes, in turn promoting c-Myc DNA binding
at E boxes [16]. In another study by Lofsted and coworkers [18] it was
demonstrated that hypoxia upregulates Mxi-1 mRNA and protein in
neuroblastoma and breast cancer cells, and Mxi-1 was conﬁrmed as
a direct HIF-1α target gene. In a murine hepatoma cell line Mxi-1 in-
duction by hypoxia was also found to be HIF-1-dependent and caused
concomitant downregulation of the c-Myc target genes [19]. Here we
also show that hypoxia augments Mxi-1 and simultaneously dimin-
ishes c-Myc expression in HMEC-1 cells. In accordance, transduction
of cells with AdHIF-1α decreased c-Myc levels, suggesting that the ef-
fect of hypoxia is primarily mediated by HIF-1α.
Interestingly, recent studies by Yoo and coworkers demonstrated
that IL-8 is upregulated in Mxi-1 knockdown cells [20]. Moreover,
by using computational analysis we found two c-Myc:Max binding
sites in the promoter region of IL-8, which suggests that IL-8 might
be directly regulated by c-Myc. Indeed, using ChIP analysis, we
reported that c-Myc binds to the promoter region of IL-8 under nor-
moxic conditions and this interaction is strikingly inhibited in re-
sponse to hypoxia. Thus, we postulate that the observed effects of
HIF isoforms on IL-8 expression are related to Mxi-1/c-Myc interac-
tions and/or their interaction with SP-1. We report also that Mxi-1
is involved in the effect of HIF-1α because the silencing of Mxi-1 re-
versed IL-8 downregulation after hypoxia or AdHIF-1α transduction.
On the other hand, IL-8 upregulation in response to HIF-2α is at
least partially mediated by c-Myc because siRNA against the latter re-
versed the induction of IL-8 expression.
Taken together, our data show that Mxi-1 is involved in downre-
gulation of IL-8 expression after HIF-1α overexpression as well as by
hypoxia in HMEC-1 cells. The possible mechanism may be related to
an increase in Mxi-1 level, a decrease in c-Myc, or disruption of
c-Myc:SP-1 and/or c-Myc:Max complex formation. On the other
side, overexpression of HIF-2α results in upregulation of IL-8 expres-
sion through induction of SP-1 activity, increase in the c-Myc level,
or stimulation of c-Myc:SP-1 and/or c-Myc:Max complex formation
(Fig. 7). Given the opposing roles of HIF isoforms on c-Myc tran-
scriptional activity and IL-8 level, the functional outcome of their
hypoxic regulation may depend on the relative expression levels of
HIF-1α and HIF-2α in a given cell type, especially if they may also
both be activated under severe (0.5% O2) and more physiological
(5.0% O2) hypoxia as well. To modulate vascular growth and cancer
cell metabolism and survival, and in turn to establish new therapies,it is reasonable to further examine the reciprocal ratio of HIF iso-
forms in a particular cell type or tumor in which the coactivation
of both isoforms is usual.
The data presented here suggest some relevance to tumor growth
and antiangiogenic therapies. The strategies based on HIF-1 inhibition
may lead to downregulation of some genes (such as VEGF) but con-
comitantly IL-8 may be increased. These results are in accordance
with the experiments of Mizukami et al. [34], who observed no differ-
ence between vascularization of tumors formed after injection of ei-
ther wild-type or HIF-1α knockdown colon cancer cells into nude
mice. In fact, in such cells, despite the inhibition of VEGF, the IL-8 syn-
thesis was upregulated [34].
However, in some tumors, e.g., human glioblastoma, expression of
HIF-2α is particularly high and it plays a more important role than
HIF-1α [35]. Therefore, it would be reasonable to investigate if such
tumors are characterized by increased IL-8 production. Then the
strategy of inhibition of HIF-2αmight be considered as additional an-
ticancer therapy. Interestingly, mithramycin A, which was able to re-
verse the effect of HIF-2α on IL-8 expression, is used as an anticancer
drug in clinics. Although the mechanism of its action is not fully un-
derstood, it is known, that mithramycin A via triggering activity of
p53 protein and inhibition of SP-1, decreases angiogenesis in tumors
[36,37].
An aberrant expression of angiogenic mediators contributes to the
development and progression of numerous diseases. This study, in re-
vealing the opposite roles played byHIF-1α andHIF-2α in the regulation
of IL-8 expression in endothelial cells, points to the potential limitations
of antiangiogenic strategies targeted at a single transcription factor.
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